143 related articles for article (PubMed ID: 30507463)
1. Hep C Calculator: an online tool for cost-effectiveness analysis of DAAs.
Chhatwal J; Chen Q; Bethea ED; Ladd MA; Mueller PP; Hutin Y; Aggarwal R
Lancet Gastroenterol Hepatol; 2018 Dec; 3(12):819. PubMed ID: 30507463
[No Abstract] [Full Text] [Related]
2. The Hep B Calculator: an online tool for cost-effectiveness analyses of treatment.
Toy M; Hutton DW; Lauer J; Bulterys M; Hutin Y; So S
Lancet Gastroenterol Hepatol; 2019 Sep; 4(9):668. PubMed ID: 31362918
[No Abstract] [Full Text] [Related]
3. Cost-Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong.
Yuen MF; Liu SH; Seto WK; Mak LY; Corman SL; Hsu DC; Lee MYK; Khan TK; Puenpatom A
Dig Dis Sci; 2021 Apr; 66(4):1315-1326. PubMed ID: 32385703
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C: An Eastern Perspective.
Dan YY; Lim SG
Gastroenterol Clin North Am; 2015 Dec; 44(4):793-805. PubMed ID: 26600220
[TBL] [Abstract][Full Text] [Related]
5. [Cost-efficacy of new antiviral treatments for chronic hepatitis C].
Lens S; Bonacci M
Aten Primaria; 2015 Oct; 47(8):479-81. PubMed ID: 26433699
[No Abstract] [Full Text] [Related]
6. Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals.
Chhatwal J; He T; Lopez-Olivo MA
Pharmacoeconomics; 2016 Jun; 34(6):551-67. PubMed ID: 26748919
[TBL] [Abstract][Full Text] [Related]
7. A cure for the high cost of hepatitis C virus treatment.
Etzion O; Ghany MG
Ann Intern Med; 2015 May; 162(9):660-1. PubMed ID: 25820765
[No Abstract] [Full Text] [Related]
8. The optimal timing of hepatitis C therapy in liver transplant-eligible patients: Cost-effectiveness analysis of new opportunities.
Cortesi PA; Belli LS; Facchetti R; Mazzarelli C; Perricone G; De Nicola S; Cesana G; Duvoux C; Mantovani LG; Strazzabosco M;
J Viral Hepat; 2018 Jul; 25(7):791-801. PubMed ID: 29406608
[TBL] [Abstract][Full Text] [Related]
9. A Cost-Effectiveness Analysis of Glecaprevir/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan.
Kawaguchi I; Chayama K; Gonzalez YS; Virabhak S; Mitchell D; Yuen C; Kumada H
Adv Ther; 2020 Jan; 37(1):457-476. PubMed ID: 31808054
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of interferon treatment for hepatitis C.
van Leeuwen DJ
JAMA; 1999 Jun; 281(22):2083-4. PubMed ID: 10367810
[No Abstract] [Full Text] [Related]
11. Cost-effectiveness of viral hepatitis B & C treatment.
Toy M
Best Pract Res Clin Gastroenterol; 2013 Dec; 27(6):973-85. PubMed ID: 24182615
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of treatment for chronic hepatitis C infection.
Bernstein D
JAMA; 2003 Oct; 290(15):1993; author reply 1994. PubMed ID: 14559948
[No Abstract] [Full Text] [Related]
13. Cost-effectiveness of treatment for chronic hepatitis C infection.
Dore GJ; Thein HH
JAMA; 2003 Oct; 290(15):1993; author reply 1994. PubMed ID: 14559947
[No Abstract] [Full Text] [Related]
14. Evaluation of cost-effectiveness of peginterferon plus ribavirin for chronic hepatitis C treatment and direct-acting antiviral agents among HIV-infected patients in the prison and community settings.
Chen CP; Cheng CY; Zou H; Cheng CH; Cheng SH; Chen CK; Chen CH; Bair MJ
J Microbiol Immunol Infect; 2019 Aug; 52(4):556-562. PubMed ID: 30360951
[TBL] [Abstract][Full Text] [Related]
15. Direct-Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype 1 Infection Are Cost-Saving.
Chhatwal J; He T; Hur C; Lopez-Olivo MA
Clin Gastroenterol Hepatol; 2017 Jun; 15(6):827-837.e8. PubMed ID: 27650326
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of interferon treatment for hepatitis C.
Henley E
JAMA; 1999 Jun; 281(22):2083; author reply 2084. PubMed ID: 10367809
[No Abstract] [Full Text] [Related]
17. Cost-effectiveness of interferon alfa 2b and ribavirin in the treatment of chronic hepatitis C.
Kim WR; Poterucha JJ; Gross JB
Hepatology; 2000 Mar; 31(3):807-8. PubMed ID: 10722315
[No Abstract] [Full Text] [Related]
18. 'HepConomics': cost-effective, indeed, but how can we pay for it?
Athanasakis K; Petrakis I; Kyriopoulos J
J Viral Hepat; 2015 Aug; 22(8):682. PubMed ID: 25727161
[No Abstract] [Full Text] [Related]
19. Cost-Utility Analysis of Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Genotype 1 and 6 in Vietnam.
Due OT; Thakkinstian A; Thavorncharoensap M; Sobhonslidsuk A; Wu O; Phuong NK; Chaikledkaew U
Value Health; 2020 Sep; 23(9):1180-1190. PubMed ID: 32940236
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of the highly effective direct-acting antivirals in the treatment of chronic hepatitis C in Hong Kong.
Lo AO; Chan HL; Wong VW; Wong GL
J Gastroenterol Hepatol; 2017 May; 32(5):1071-1078. PubMed ID: 28449343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
